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Case ReportsSapien XT implantation under direct vision as a bail-out procedure in
case of hostile aortic root: A reasonable alternative for stentless
bioprosthesis reoperationChiara Tessari, MD, Augusto D’Onofrio, MD, Cosimo Guglielmi, MD, and Gino Gerosa, MD, Padua, ItalyReoperations for stentless bioprostheses structural dys-
function are quite common. These procedures represent
a surgical challenge because complete aortic root
replacement might be required due to severe root calci-
fication.1 Valve-in-valve transcatheter aortic valve re-
placement (ViV-TAVR) has been proposed as an
alternative treatment in high-risk patients requiring aor-
tic valve reoperations.2 However, ViV-TAVR in biopros-
theses has raised some concern related to the risk
of coronary ostia occlusion by prosthetic leaflets.3 We
present a case of a patient with a stentless valve dysfunc-
tion who was scheduled for conventional reoperation but
who finally underwent ViV-TAVR for the presence of
massive calcification of the aortic root and particularly
of the coronary ostia, which made isolated valve re-
placement as well as Bentall operation technically
impossible.CLINICAL SUMMARY
A 65-year-old man was admitted to Padua University
Hospital Cardiac Surgery Division for congestive heart fail-
ure (New York Heart Association functional class IV). In
2001 the patient underwent aortic valve replacement with
a 25 mm Biocor Porcine Stentless Valve (St Jude Medical,
Inc, St Paul, Minn) (Figure 1) and closure of a fistula be-
tween the left ventricle and the right atrium due to active
aortic valve destructive bacterial endocarditis that caused
rupture of the aortoventricular junction. The pericardial
sheath wrapping the stentless valve was used to reconstruct
the aortic root suturing the lower margin deep into the left
ventricular outflow tract (LVOT) and the upper margin
beneath the coronary ostia. At the time of admission in
2012, Doppler echocardiography showed severe aortic re-
gurgitation due to rupture and prolapse of the bioprosthesis
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erate pulmonary hypertension (46 mm Hg). The patient’s
body mass index and body surface area were 23.05 and
1.82 m2, respectively. EuroSCORE I was 8.63%, Euro-
SCORE II was 4.86%, and Society of Thoracic Surgeons
mortality score 6.3%.
Due to relatively young age and to the absence of severe
comorbidities, the patient was scheduled for conventional
replacement of the aortic bioprosthesis.
According to the operative strategy the patient under-
went full resternotomy and cardiopulmonary bypass was
instituted with the cannulation of the ascending aorta
and the right atrium. After aortic crossclamping, the as-
cending aorta was opening and cold blood cardioplegia
was administered with selective coronary ostia cannula-
tion. The degenerated aortic bioprosthesis was inspected
confirming the echocardiographic findings, in particular
a fracture of the left coronary leaflet causing leaflet pro-
lapse into the LVOTwas observed. The pericardial sheath,
which is part of the Biocor stentless bioprosthesis, ap-
peared extremely calcified (Figure 2, A) either in the sub-
valvular portion of the LVOT and in proximity of the
coronary ostia, which made coronary ostia isolation for
a Bentall procedure technically impossible. Valve leaflets
were excised but removal of the pericardial sheath would
carry a very high risk of damage to the aortoventricular
junction, to the aortic root, and to the LVOT. A conven-
tional aortic valve replacement was not feasible due to
the impossibility of passing any needle across the calcified
annulus. Even a sutureless bioprosthesis was not implant-
able because the 3 guiding sutures were too difficult to
pass due to the extremely hard calcifications. Thus, after
measuring the annulus with a 24 mm Hegar, a 26 mm Sa-
pien XT valve (Edwards Lifesciences, Irvine, Calif) was
implanted under direct vision through the aortotomy.
The bioprosthesis was partially crimped on the Ascendra
2 delivery system (Edwards Lifesciences, Irvine, Calif)
and it was deployed without complications (Figure 3).
Valve positioning was visually assessed: coronary ostia
were free from obstructions and there were no visible par-
avalvular leaks. At the end of the operation intraoperative
transesophageal echocardiography showed a well func-
tioning Sapien valve without paravalvular leaks
(Figure 2, B). CPB time was 117 minutes and aortic
crossclamp time was 60 minutes. The patient had anery c March 2013
FIGURE 1. Biocor porcine stentless valve.
FIGURE 2. Intraoperative transesophageal images. A, Intraoperative
transesophageal echocardiographic image showing the calcified aortic
root (arrow). B, Intraoperative transesophageal echocardiographic image
showing good positioning of the Sapien XT valve (Edwards Lifesciences,
Irvine, Calif) without aortic regurgitation.
Case Reportsuneventful hospital stay and was successfully discharged.
Predischarge echocardiography showed a well-functioning
aortic bioprosthesis and no paravalvular nor intravalvular
leaks. Peak and mean transprosthetic gradients were 23
and 12.5 mm Hg, respectively. Effective orifice area was
1.86 cm2.DISCUSSION
This case describes a bail-out implantation of a Sapien
XT transcatheter valve under direct vision during conven-
tional surgery for stentless valve dysfunction with a hostile
aortic root due to massive calcifications. Although con-
ventional aortic valve replacement is still the treatment
of choice for patients with severe symptomatic aortic
valve stenosis, new treatment options like sutureless aor-
tic valve implantation and TAVR have been proposed in
high-risk or inoperable patients. In particular, ViV-
TAVR has shown to be safe and effective in case of failure
of aortic bioprostheses, both stented and stentless.4
Concerns still remain with respect to TAVR-related
vascular injury, stroke, paravalvular leak, and valve dura-
bility. All these issues limit TAVR use in young and/orThe Journal of Thoracic and Calow-risk patients.5 However, direct-vision implantation
of a sutureless valve could significantly reduce all the
above-mentioned TAVR-related complications because
there are no extra vascular accesses needed, there is no
catheter manipulation of the aortic arch and the aortic
wall, there is no balloon valvuloplasty, and there is the
possibility to visually assess the correct position of the
valve with respect to coronary ostia. Additionally, the in-
cidence of paravalvular leaks can be reduced because the
diseased aortic valve can be partially decalcified. The use
of sutureless aortic bioprostheses is now rapidly increas-
ing, but the experience is still limited. In our case the
use of a sutureless aortic valve bioprosthesis was not
feasible due to the impossibility to cross the calcified
pericardium with the guiding sutures. We therefore de-
cided to use as a bail-out procedure the Sapien XT valve.
The TAVR has all the benefits of a sutureless valve
without requiring positioning of the guiding sutures. Fur-
thermore, during ViV-TAVR, there is no need for
complete crimping of the valve with potential benefits
in terms of valve durability due to reduced stress of the
leaflets.rdiovascular Surgery c Volume 145, Number 3 e37
FIGURE 3. Intraoperative view. A, The Sapien XT valve (Edwards Lifesciences, Irvine, Calif) is partially crimped on the Ascendra 2 System (Edwards
Lifesciences, Irvine, Calif). B, The valve on the delivery system is placed in its correct position under direct vision through the aortotomy. C, The balloon is
inflated and the bioprosthesis is deployed. D, The valve is in its final position with the leaflets open.
Case ReportsCONCLUSIONS
Direct-vision ViV-TAVR is a reasonable option in case of
hostile aortic root during aortic valve re-replacement
procedures.References
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